Laurus Labs Share News - Latest Updates, Live News & More

Latest news about Laurus Labs

Laurus Labs Reports Strong Q1 Performance with 31% Revenue Growth, CDMO Business Drives Margins 2 days ago

Laurus Labs Limited reported robust Q1 financial results with total income from operations reaching INR 1,570.00 crores, a 31% year-on-year growth. The CDMO business emerged as a key growth driver, with sales reaching INR 493.00 crores. The company announced three major capacity expansions and plans to invest INR 5,000.00 crores over the next 4-5 years. Management expects the CDMO segment to potentially contribute 50% of revenue in the medium term, up from the current 30%. The company maintains a positive outlook with projected growth in the CDMO segment and stable ARV business performance.

Laurus Labs Targets 25% EBITDA Margins, Secures 531.77 Acres for Expansion 3 days ago

Laurus Labs Secures 532-Acre Land for ₹5,630 Crore Pharma Zone in Andhra Pradesh 3 days ago

Laurus Labs Reports Strong Q1 Results, Exceeding Estimates Across Key Metrics 6 days ago

Laurus Labs' Exports Soar by 221%, Reaching $106 Million Jul 10, 2025

More news about Laurus Labs

16Jun 25

Laurus Labs Doubles Exports in May, Showcasing Remarkable Growth

Laurus Labs, a pharmaceutical company, has experienced a significant increase in its export performance for May. The company's exports have more than doubled, showing a 104.00% increase compared to the same period last year. This surge indicates an expansion of Laurus Labs' global footprint and suggests potential for enhanced revenue from international sales. The growth also implies improved operational efficiency and a strengthened position in the global pharmaceutical market.

26Apr 25

Laurus Labs Reports Strong Q4 FY25, Eyes 24% EBITDA Margin in FY26

Laurus Labs Limited reported robust Q4 FY25 results with 19% revenue growth to Rs 1,720.00 crore and tripled net profit to Rs 234.00 crore. For FY26, the company projects EBITDA margins of 24.00-24.50% and expects better revenue growth than FY25. The CDMO segment is anticipated to match generics contribution in the next five years. Strong demand in CDMO, asset leverage, and operational efficiency are driving the positive outlook.

24Apr 25

Laurus Labs Q4 Profit Surges 210%, Margins Exceed 20% for Second Quarter

Laurus Labs posted a consolidated net profit of ₹233.60 crore in Q4 FY24, up 210% year-over-year. Revenue increased by 18.97% to ₹1,424.50 crore, while EBITDA grew 74% to ₹419 crore. EBITDA margins expanded to 24.5%, marking the second consecutive quarter above 20%. However, annual revenue for FY24 declined 16.20% to ₹5,067.20 crore, with net profit down 78.89% to ₹168.20 crore.

15Apr 25

Laurus Labs Secures USFDA Approval for API Facility in Andhra Pradesh

Laurus Labs Limited has received the Establishment Inspection Report (EIR) from the USFDA for its API manufacturing facility in Atchutapuram, Andhra Pradesh. The inspection, conducted from January 27 to 31, 2025, validates the company's compliance with good manufacturing practices. This approval strengthens Laurus Labs' position in the global pharmaceutical supply chain and potentially opens up new opportunities in the U.S. market.

11Apr 25

Laurus Labs Reports Robust Export Growth; Q4 FY25 Results Anticipated

Laurus Labs, a leading Indian CDMO, reported an 18% YoY increase in total exports to $53 million, with Q4 exports surging 60% YoY. The company will announce its Q4 and FY25 results on April 24, 2025, along with considering a 2nd Interim Dividend. An earnings call is scheduled for the same day at 5:00 PM IST. Laurus Labs, founded in 2005, is a global leader in API manufacturing with 14 manufacturing sites and over 6,700 employees.

07Mar 25

Laurus Labs Invests ₹83.3 Crore in KRKA Pharma JV for New Manufacturing Facility

Laurus Labs Limited has approved an investment of ₹83.3 crore in its joint venture, KRKA Pharma Private Limited. The total investment of ₹170 crore, including ₹86.7 crore from co-venturer KRKA d.d., Novo Mesto, Slovenia, will be used to acquire land for a new manufacturing facility, cover initial setup costs, and produce finished products for new markets, including India. The shareholding ratio will remain at 51:49 (KRKA d.d., Novo Mesto : Laurus Labs). The investment, expected to be completed by March 31, 2025, aligns with Laurus Labs' long-term growth strategy in the pharmaceutical industry.

21Feb 25

Laurus Labs Faces Delay in USAID HIV Funds Release Despite Favorable Court Ruling

Laurus Labs, a major pharmaceutical company, has won a court ruling regarding USAID HIV funds but is unable to access them. This delay could impact the company's HIV drug production and distribution, potentially affecting operational targets and financial performance. The situation introduces uncertainty into Laurus Labs' financial outlook, with potential implications for its market position and investor confidence. No official statement has been released by the company regarding this matter.